I
Ioannis Mantzaris
Researcher at Albert Einstein College of Medicine
Publications - 99
Citations - 1580
Ioannis Mantzaris is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 59 publications receiving 847 citations. Previous affiliations of Ioannis Mantzaris include Yeshiva University & Montefiore Medical Center.
Papers
More filters
Journal ArticleDOI
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients.
Abi Vijenthira,Inna Y. Gong,Thomas Andrew Fox,Stephen Booth,Gordon Cook,Bruno Fattizzo,Fernando Martín-Moro,Jerome Razanamahery,John Riches,Jeffrey I. Zwicker,Rushad Patell,Marie-Christiane Mb Vekemans,Lydia Scarfò,Thomas Chatzikonstantinou,Halil Yildiz,Raphaël Lattenist,Ioannis Mantzaris,William A. Wood,Lisa K. Hicks,Lisa K. Hicks +19 more
TL;DR: Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying and adults aged ≥60 years have significantly higher mortality; pediatric patients appear to be relatively spared.
Journal ArticleDOI
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Luis A. Carvajal,Daniela Ben Neriah,Adrien Senecal,Lumie Benard,Victor Thiruthuvanathan,Tatyana Yatsenko,Swathi Rao Narayanagari,Justin C. Wheat,Tihomira I. Todorova,Kelly Mitchell,Charles A. Kenworthy,Vincent Guerlavais,D. Allen Annis,Boris Bartholdy,Britta Will,Jesus Anampa,Ioannis Mantzaris,Manuel Aivado,Robert H. Singer,Robert A. Coleman,Amit Verma,Ulrich Steidl +21 more
TL;DR: Dual inhibition of MDMX and MDM2 by an α-helical p53-stapled peptide (ALRN-6924) results in robust antitumor activity in acute myeloid leukemia and provides mechanistic insight to support further testing of ALRN- 6924 as a therapeutic approach in AML and other cancers with wild-type p53.
Journal ArticleDOI
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Ahmed Abbasi,Stephen Peeke,Nishi Shah,Jennat Mustafa,Fariha Khatun,Amanda Lombardo,Michelly Abreu,Richard Elkind,Karen Fehn,Alyssa De Castro,Yanhua Wang,Olga Derman,Randin Nelson,Joan Uehlinger,Kira Gritsman,R. Alejandro Sica,Noah Kornblum,Ioannis Mantzaris,Aditi Shastri,Murali Janakiram,Mendel Goldfinger,Amit Verma,Ira Braunschweig,Lizamarie Bachier-Rodriguez +23 more
TL;DR: Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting and was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS.
Journal ArticleDOI
miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.
Tushar D. Bhagat,Li Zhou,Lubomir Sokol,Rachel Kessel,Gisela Caceres,Krishna Gundabolu,Roni Tamari,Shanisha Gordon,Ioannis Mantzaris,Tomasz Jodlowski,Yiting Yu,Xiaohong Jing,Rahul Polineni,Kavi Bhatia,Andrea Pellagatti,Jacqueline Boultwood,Suman Kambhampati,Ulrich Steidl,Cy A. Stein,Wenjun Ju,Gang Liu,Paraic A. Kenny,Alan F. List,Markus Bitzer,Markus Bitzer,Amit Verma +25 more
TL;DR: The role of miR-21 is demonstrated in regulating overactivated TGF-β signaling in MDS by directly bind to the 3'UTR of SMAD7 and reduce its expression in hematopoietic cells.
Journal ArticleDOI
Pharmacological inhibition of the transcription factor PU.1 in leukemia
Iléana Antony-Debré,Ananya Paul,Joana Leite,Kelly Mitchell,Hye Mi Kim,Luis A. Carvajal,Tihomira I. Todorova,Kenneth Huang,Arvind Kumar,Abdelbasset A. Farahat,Boris Bartholdy,Swathi Rao Narayanagari,Jiahao Chen,Alberto Ambesi-Impiombato,Adolfo A. Ferrando,Ioannis Mantzaris,Evripidis Gavathiotis,Amit Verma,Britta Will,David W. Boykin,W. David Wilson,Gregory M.K. Poon,Ulrich Steidl +22 more
TL;DR: This study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.